HUMATIN Drug Patent Profile
✉ Email this page to a colleague
When do Humatin patents expire, and when can generic versions of Humatin launch?
Humatin is a drug marketed by King Pfizer, Parkedale, and Parke Davis. and is included in three NDAs.
The generic ingredient in HUMATIN is paromomycin sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the paromomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Humatin
A generic version of HUMATIN was approved as paromomycin sulfate by HERITAGE PHARMS on December 14th, 2007.
Summary for HUMATIN
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Patent Applications: | 4,465 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HUMATIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HUMATIN
US Patents and Regulatory Information for HUMATIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pfizer | HUMATIN | paromomycin sulfate | CAPSULE;ORAL | 062310-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Parkedale | HUMATIN | paromomycin sulfate | CAPSULE;ORAL | 060521-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Parke Davis | HUMATIN | paromomycin sulfate | SYRUP;ORAL | 060522-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |